Hoth Therapeutics shares are trading higher after the company received IRB approval to proceed with its first-in-human phase 2a trial of HT-001 for skin toxicities associated with epidermal growth factor receptor inhibitors
Portfolio Pulse from Benzinga Newsdesk
Hoth Therapeutics has received IRB approval to proceed with its first-in-human phase 2a trial of HT-001 for skin toxicities associated with epidermal growth factor receptor inhibitors.
June 14, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Hoth Therapeutics' stock price is trading higher after receiving IRB approval for its phase 2a trial of HT-001.
Hoth Therapeutics has received IRB approval to proceed with its phase 2a trial of HT-001, which is a significant milestone for the company. This news is likely to boost investor confidence in the company's progress and potential, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100